亞洲領(lǐng)先的制藥行業(yè)盛會(huì)——世界制藥原料中國(guó)展（CPHI & PMEC China）于2025年6月24日至26日在上海新國(guó)際博覽中心（SNIEC）隆重舉辦，匯聚了來(lái)自全球醫(yī)藥供應(yīng)鏈各環(huán)節(jié)的供應(yīng)商與采購(gòu)商。

CPHI & PMEC China, Asia’s premier pharmaceutical event connecting suppliers and buyers across the entire pharmaceutical supply chain, was held from June 24–26, 2025, at Shanghai New International Expo Centre (SNIEC).

海南中和藥業(yè)團(tuán)隊(duì)積極參與了此次享有盛譽(yù)的展會(huì)，展示了豐富的產(chǎn)品組合，包括原料藥（API）、成品制劑以及創(chuàng)新的多肽類化妝品產(chǎn)品。

Hainan Zhonghe Pharmaceutical’s team actively participated in this prestigious exhibition, presenting a diverse portfolio including active pharmaceutical ingredients (APIs), finished dosage formulations, and innovative peptide-based cosmetics.

本屆展會(huì)吸引了來(lái)自166個(gè)國(guó)家的3,500多家展商及超過(guò)90,000名專業(yè)觀眾，展商及觀眾來(lái)源包括中國(guó)、美國(guó)、印度、獨(dú)聯(lián)體國(guó)家、東南亞、歐洲和非洲等地區(qū)。展會(huì)面積達(dá)23萬(wàn)平方米，成為全球行業(yè)交流、創(chuàng)新與合作的重要平臺(tái)。

This year’s CPHI Shanghai brought together more than 3,500 exhibitors and over 90,000 professional visitors from 166 countries, including China, United States, India, the CIS region, southeast Asia, Europe and Africa. Spanning an impressive 230,000 square meters, the exhibition served as a global hub for industry dialogue, innovation, and partnership.

在為期三天的展會(huì)期間，中和藥業(yè)重點(diǎn)展示了其已上市和在研產(chǎn)品，吸引了眾多國(guó)際專家和業(yè)內(nèi)人士的廣泛關(guān)注。展位不僅是展示產(chǎn)品的平臺(tái)，更是深入交流、技術(shù)探討和戰(zhàn)略合作的橋梁。通過(guò)面對(duì)面的溝通，不僅加深了現(xiàn)有合作關(guān)系，還發(fā)掘了新的商業(yè)機(jī)會(huì)。這些交流也為公司洞察全球市場(chǎng)需求提供了寶貴信息，增強(qiáng)了新老客戶對(duì)公司的信心。

Throughout the three-day event, Zhonghe Pharmaceutical highlighted both its commercialized and pipeline products, drawing interest from a wide range of international experts and industry stakeholders. The exhibition booth served as a platform for in-depth discussions, technical exchanges, and strategic partnership development, reinforcing existing relationships and uncovering new business opportunities. These face-to-face interactions provided valuable insights into global market demands and strengthened confidence among new and long-standing clients alike.

海南中和藥業(yè)立足中國(guó)，放眼全球，將繼續(xù)依托強(qiáng)大的產(chǎn)業(yè)鏈，不斷提升產(chǎn)品質(zhì)量與服務(wù)水平，為全球市場(chǎng)提供高品質(zhì)的多肽類醫(yī)藥產(chǎn)品。中和藥業(yè)將始終堅(jiān)守初心，堅(jiān)持持續(xù)創(chuàng)新與國(guó)際化，致力于成為全球領(lǐng)先的多肽類藥品制造商。

Hainan Zhonghe Pharmaceutical remains firmly rooted in China with a global outlook. The company will continue to leverage its strong industrial chain, elevate product quality and service standards, and deliver high-quality pharmaceutical and peptide-based solutions to the international market. As part of its ongoing commitment to innovation and globalization, Zhonghe strives to become a world-leading manufacturer in the field of peptide pharmaceutical.

歡迎掃描二維碼，瀏覽我們的藥品、原料藥及化妝品產(chǎn)品目錄。

Please scan QR code to check our FDFs, APIs and cosmetic catalogs.